Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pritelivir dose-finding in genital HSV-2
NCT01047540Phase 2Completed
- Sponsor
- AiCuris
- Start
- Mar 2010
- Primary completion
- Dec 2010
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pritelivir in genital herpes (5 arms), sponsored by AiCuris. Primary endpoint: Suppression of Herpes Simplex Virus Replication (Shedding Rate) at 28 days. Started Mar 2010; status: completed.
02
Drugs
pritelivir
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT01047540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047540.